Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
618.03-3.18 (-0.51%)
As of 3:22PM EDT. Market open.
| Previous close | 621.21 |
| Open | 621.00 |
| Bid | 617.58 x 1300 |
| Ask | 618.06 x 1400 |
| Day's range | 614.55 - 627.46 |
| 52-week range | 271.37 - 664.64 |
| Volume | 310,008 |
| Avg. volume | 1,245,659 |
| Market cap | 65.754B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 23.93 |
| EPS (TTM) | 25.83 |
| Earnings date | 03 Nov 2020 - 09 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 672.04 |
- Zacks
Regeneron's (REGN) Q2 Earnings & Sales Surpass Estimates
Regeneron (REGN) beats on Q2 earnings and sales on solid performance of Dupixent and oncology drug, Libtayo.
- Zacks
Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates
Regeneron (REGN) delivered earnings and revenue surprises of 14.93% and 9.05%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- Motley Fool
Eli Lilly's COVID-19 Treatment Candidate Will Be the First Tested in NIH's Phase 3 Study
The National Institutes of Health is starting a head-to-head trial of several antibody treatment candidates.
© 2020 Verizon Media. All rights reserved.
